Aerovate Therapeutics Inc
NASDAQ:AVTE

Watchlist Manager
Aerovate Therapeutics Inc Logo
Aerovate Therapeutics Inc
NASDAQ:AVTE
Watchlist
Price: 2.63 USD
Market Cap: 75.9m USD
Have any thoughts about
Aerovate Therapeutics Inc?
Write Note

Aerovate Therapeutics Inc
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Aerovate Therapeutics Inc
Cash from Operating Activities Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Aerovate Therapeutics Inc
NASDAQ:AVTE
Cash from Operating Activities
-$56.8m
CAGR 3-Years
-93%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash from Operating Activities
$16.5B
CAGR 3-Years
-10%
CAGR 5-Years
4%
CAGR 10-Years
12%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Operating Activities
$10B
CAGR 3-Years
0%
CAGR 5-Years
2%
CAGR 10-Years
0%
Amgen Inc
NASDAQ:AMGN
Cash from Operating Activities
$7.3B
CAGR 3-Years
-6%
CAGR 5-Years
-6%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Operating Activities
-$944m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-10%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Operating Activities
$4.2B
CAGR 3-Years
-11%
CAGR 5-Years
12%
CAGR 10-Years
18%

See Also

What is Aerovate Therapeutics Inc's Cash from Operating Activities?
Cash from Operating Activities
-56.8m USD

Based on the financial report for Dec 31, 2023, Aerovate Therapeutics Inc's Cash from Operating Activities amounts to -56.8m USD.

What is Aerovate Therapeutics Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
-93%

Over the last year, the Cash from Operating Activities growth was -45%. The average annual Cash from Operating Activities growth rates for Aerovate Therapeutics Inc have been -93% over the past three years .

Back to Top